102 / 1631
Immune-related adverse events
•
Overall, grade 3 or 4 irAEs are observed in 7–12% of patients with solid
tumors who receive single anti-PD-1 or anti-PD-L1 antibodies.
•
A predictable pattern of irAEs has been observed in such patients;
dermatologic and gastrointestinal toxicities appear early, and hepatic
toxicities or endocrinopathies are seen later
•
In patients with lymphoid neoplasms, irAEs of any grade appear in 72%-
100% of patients.
•
Common irAEs include thrombocytopenia, neutropenia, fatigue, infusion
reaction, hypothyroidism, rash, diarrhea, nausea, pyrexia, pneumonitis,
diarrhea, fatigue, back pain, decrease in platelets, dry skin, and cough.